CD274 and neoplasm: ICIs act by enhancing the host immune response against the tumor through the blockage of immune checkpoints (including cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), the programmed death-1 receptor (PD-1), and its ligand (PD-L1)).